S Gandon, S Lion - Proceedings of the National Academy of …, 2022 - National Acad Sciences
The limited supply of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raises the question of targeted vaccination. Many countries have opted to …
There is growing concern that Coronavirus Disease 2019 (COVID-19) vaccine fatigue will be a major obstacle in maintaining immunity in the general population. In this study, we …
Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional phase 3 …
M Shrotri, E Fragaszy, V Nguyen… - Nature …, 2022 - nature.com
Vaccination constitutes the best long-term solution against Coronavirus Disease-2019; however, vaccine-derived immunity may not protect all groups equally, and the durability of …
SS DeRoo, NJ Pudalov, LY Fu - Jama, 2020 - jamanetwork.com
(COVID-19) pandemic, hopefully, will be a globally implemented, safe vaccination program that has broad clinical and socioeconomic benefits. Dozens of vaccines are in development …
J Wang, C Deng, M Liu, Y Liu, L Li, Z Huang… - Nature …, 2022 - nature.com
The effectiveness of a 3rd dose of SARS-CoV-2 vaccines waned quickly in the Omicron- predominant period. In response to fast-waning immunity and the threat of Omicron variant …
JE Ebinger, J Fert-Bober, I Printsev, M Wu, N Sun… - Nature medicine, 2021 - nature.com
In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n= 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition …
INTRODUCTION Mass vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) offers the most efficient public health intervention to control the COVID-19 …
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infections in vaccinated individuals and reinfections in previously infected individuals have become …